David Dai
Stock Analyst at UBS
(0.40)
# 4,013
Out of 4,761 analysts
18
Total ratings
18.75%
Success rate
-26.05%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IMCR Immunocore Holdings | Initiates: Sell | $24 | $29.92 | -19.79% | 1 | Oct 24, 2024 | |
| NUVL Nuvalent | Initiates: Neutral | $100 | $79.49 | +25.80% | 1 | Oct 24, 2024 | |
| BPMC Blueprint Medicines | Initiates: Neutral | $88 | $92.25 | -4.61% | 1 | Oct 24, 2024 | |
| CATX Perspective Therapeutics | Initiates: Buy | $20 | $2.78 | +619.42% | 1 | Oct 24, 2024 | |
| NRIX Nurix Therapeutics | Initiates: Buy | $35 | $16.87 | +107.47% | 1 | Oct 24, 2024 | |
| MRUS Merus | Initiates: Buy | $72 | $47.37 | +51.99% | 1 | Oct 24, 2024 | |
| KURA Kura Oncology | Initiates: Buy | $27 | $8.25 | +227.27% | 1 | Oct 24, 2024 | |
| JANX Janux Therapeutics | Initiates: Buy | $69 | $36.01 | +91.61% | 1 | Oct 24, 2024 | |
| IDYA IDEAYA Biosciences | Initiates: Buy | $50 | $21.85 | +128.83% | 1 | Oct 24, 2024 | |
| IOVA Iovance Biotherapeutics | Initiates: Buy | $17 | $5.78 | +194.12% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $9.03 | +232.23% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $27.85 | +115.44% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $16.38 | +125.89% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.97 | +2,776.52% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $12.56 | +218.47% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $2.76 | +1,349.28% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.05 | +2,339.02% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $42.42 | +22.58% | 1 | Mar 17, 2020 |
Immunocore Holdings
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $29.92
Upside: -19.79%
Nuvalent
Oct 24, 2024
Initiates: Neutral
Price Target: $100
Current: $79.49
Upside: +25.80%
Blueprint Medicines
Oct 24, 2024
Initiates: Neutral
Price Target: $88
Current: $92.25
Upside: -4.61%
Perspective Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $20
Current: $2.78
Upside: +619.42%
Nurix Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $35
Current: $16.87
Upside: +107.47%
Merus
Oct 24, 2024
Initiates: Buy
Price Target: $72
Current: $47.37
Upside: +51.99%
Kura Oncology
Oct 24, 2024
Initiates: Buy
Price Target: $27
Current: $8.25
Upside: +227.27%
Janux Therapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $36.01
Upside: +91.61%
IDEAYA Biosciences
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $21.85
Upside: +128.83%
Iovance Biotherapeutics
Oct 24, 2024
Initiates: Buy
Price Target: $17
Current: $5.78
Upside: +194.12%
Oct 24, 2024
Initiates: Buy
Price Target: $30
Current: $9.03
Upside: +232.23%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $27.85
Upside: +115.44%
Oct 24, 2024
Initiates: Buy
Price Target: $37
Current: $16.38
Upside: +125.89%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.97
Upside: +2,776.52%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $12.56
Upside: +218.47%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $2.76
Upside: +1,349.28%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.05
Upside: +2,339.02%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $42.42
Upside: +22.58%